Notification That Annual Report Will Be Submitted Late (nt 10-k)
April 02 2013 - 6:03AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM 12b-25
NOTIFICATION OF LATE FILING
SEC FILE NUMBER
000-54402
CUSIP NUMBER
090655101
(Check one):
|
[X] Form 10-K [_] Form
20-F [_] Form
11-K [_] Form
10-Q [_] Form
10-D
[_] Form N-SAR [_] Form
N-CSR
|
|
|
For Period Ended:
December 31, 2012
[_] Transition Report on Form 10-K
[_] Transition Report on Form 20-F
[_] Transition Report on Form 11-K
[_] Transition Report on Form 10-Q
[_] Transition Report on Form N-SAR
For the Transition Period Ended: ____________________
|
Read attached instruction
sheet before preparing form. Please print or type.
Nothing in this form shall be construed
to imply that the Commission has verified any information contained herein.
If the notification relates to a portion
of the filing checked above, identify the item(s) to which the notification relates:
PART I - REGISTRANT INFORMATION
BIORESTORATIVE THERAPIES, INC
.
Full Name of Registrant
Former Name if
Applicable
555 Heritage
Drive
Address of Principal
Executive Office (Street and Number)
Jupiter, FL
33458
City, State and
Zip Code
PART II - RULES 12b-25(b) AND (c)
If the subject report could not be filed
without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed.
(Check box if appropriate)
[X]
|
(a)
|
The
reasons described in reasonable detail
in Part III of this form could not be
eliminated without unreasonable effort
or expense;
|
[X]
|
(b)
|
The
subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, 11-K or Form N-SAR, or portion thereof,
will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition
report on Form 10-Q, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date;
and
|
[ ]
|
(c)
|
(The accountant's statement or other exhibit required by Rule 12b-25(c) has been
attached if applicable.
|
PART III - NARRATIVE
State below in reasonable detail the reasons
why Forms 10-K, 11-K, 20-F, 10-Q, N-SAR, or the transition report or portion thereof, could not be filed within the prescribed
time period.
The Company was unable
to file its Annual Report on Form 10-K for the year ended December 31, 2012 within the prescribed time period due to the unavailability
of certain persons needed to provide the necessary information.
PART IV — OTHER INFORMATION
|
|
|
|
|
|
(1)
|
Name and telephone number of person to contact in regard to this notification
|
|
|
Mark Weinreb
|
|
(561)
|
|
904-6070
|
|
(Name)
|
|
(Area Code)
|
|
(Telephone Number)
|
|
(2)
|
Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange
Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such
shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify
report(s).
|
|
|
[
X
] Yes [ ] No
|
|
|
(3)
|
Is it anticipated that any significant change in results of operations from the corresponding
period for the last fiscal year will be reflected by the earnings statements to be included in the subject
report or portion thereof?
|
|
|
[
X
] Yes [ ] No
|
|
|
If so, attach an explanation of the anticipated change, both narratively and quantitatively,
and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.
|
Explanation of Anticipated Change
It is anticipated that the Company will
report a net loss of $6,536,722 for the year ended December 31, 2012 as compared to a net loss of $4,073,937 for the year ended
December 31, 2011.
BIORESTORATIVE THERAPIES, INC.
(Name of Registrant as Specified in Charter)
has caused this notification to be signed
on its behalf by the undersigned thereunto duly authorized.
|
|
|
|
Date
April 1, 2013
|
By:
|
/s/ Mark Weinreb
|
|
|
Mark Weinreb
Chief Executive Officer
|
INSTRUCTION: The form may be signed by
an executive officer of the registrant or by any other duly authorized representative. The name and title of the person signing
the form shall be typed or printed beneath the signature. If the statement is signed on behalf of the registrant by an authorized
representative (other than an executive officer), evidence of the representative's authority to sign on behalf of the registrant
shall be filed with the form.
ATTENTION
Intentional misstatements or omissions
of fact constitute Federal Criminal Violations (See 18 U.S.C. 1001)
Trimol (CE) (USOTC:TMOL)
Historical Stock Chart
From Apr 2024 to May 2024
Trimol (CE) (USOTC:TMOL)
Historical Stock Chart
From May 2023 to May 2024